
Commentary|Videos|June 13, 2025
Dr Schetelig on Haploidentical vs Mismatched Transplant Efficacy in AML/ALL/MDS
Author(s)Johannes Schetelig, MD, MSc
Fact checked by: Ashling Wahner , Caroline Seymour
Johannes Schetelig, MD, discusses outcomes with haploidentical related vs mismatched unrelated donor transplantation in high-risk AML, ALL, and MDS.
Advertisement
Johannes Schetelig, MD, director of medical research at DKMS; as well as a professor at Technical University Dresden, discussed findings from the phase 2/3 HAMLET trial (NCT03275636) comparing survival outcomes with haploidentical related and single human leukocyte antigen loci–mismatched unrelated donor transplantation in patients with high-risk acute myeloid leukemia, acute lymphoblastic leukemia, and myelodysplastic syndrome.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Single-Center, Retrospective Data Show Low Rate of Lifileucel Infusion Following Referral in Advanced Melanoma
5




































